DMN:FRA
Diamyd Medical AB
€ ०.०६३
०.००%
(०.००) 1D
नोभेम्बर १९, ०८:०१:५२ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.९७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.९७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
TradingView
·
१ घण्टा पहिले
Stock Market: Will S&P 500 Open Up or Down Today?
Chattanooga Times Free Press
·
१ घण्टा पहिले
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
BigGo Finance
·
२ घण्टा पहिले
UBS Sets S&P 500 Target of 8,200 by End-2027, Implying Roughly 12% Upside, But Cuts Rating to Neutral
FOREX.com
·
२ घण्टा पहिले
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB